SG2000: Phase II started

Spirogen began an open-label, U.S. Phase II trial to evaluate 30 µg/m 2/day SG2000 for the first 3 days of a 21-day cycle in about 50 patients. Spirogen has rights to SG2000 from Ipsen. Celtic Therape...